Bryan E. Stuart has served as Chief Executive Officer and a member of the Board of Directors at Atavistik Bio since July 2023. Bryan has more than 20 years of experience in executive leadership, corporate strategy, and business development in biopharma industry. He was most recently CEO of Fulcrum Therapeutics, where he initially served as Chief Operating Officer. Prior to joining Fulcrum, he served as president and CEO of Yarra Therapeutics (a subsidiary of Array BioPharma) and CEO of Kastle Therapeutics, both companies focused on developing therapies for rare and severe diseases. Previously, Mr. Stuart served as Chief Business Officer of Civitas Therapeutics (acquired by Acorda Therapeutics) and also led business development, corporate development and strategy at both EKR Therapeutics (acquired by Chiesi Farmaceutici) and Ovation Pharmaceuticals (acquired by Lundbeck A/S).
Mr. Stuart earned his MBA from the Kellogg School at Northwestern University and a BS from the University of Illinois.